dCDK9-202

dCDK9-202 : Degrader (PROTAC) of CDK9

Structure

SERP Rating

In Cells

(2 ratings)

In Model Organisms

(2 ratings)

note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars.

Probe dCDK9-202 is in the process of SERP review.

Please continue to check back for new reviews and commentary.

Information

CDK9

Degrader (PROTAC)

10 nM, up to 25 nM

In Vitro Validations

No in Vitro Validations

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency assay, off target (cells): dCDK9-202 was evaluated for its target selectivity in the TC-71 cell line. Among CDKs, compound dCDK9-202 induced the degradation of CDK9 with high selectivity within 8 h. In addition, compound dCDK9-202 did not induce acute depletion of IKZF1/3, which are known off-targets of CRBN E3 ligands as molecular glues. The downregulation of CDK4/5/6/8/11 and IKZF3 was observed after 12 h treatment with dCDK9-202, suggesting a secondary effect.

Potency assay, off target (cells): dCDK9-202 was highly potent and effective in the inhibition of multiple cancer cell lines and achieved IC50 values of 40.9 nM in the T778 cell line (liposarcoma), 83.3 nM in the A-375 cell line (melanoma), 85.3 nM in the MES-SA cell line (uterine sarcoma), 79.6 nM in the MDA-MB-231 cell line (breast cancer), 75.4 nM in the A-673 cell line (Ewing sarcoma), 57.0 nM in the NCI-H226 cell line (lung cancer), 23.4 nM in the NALM6 cell line (B cell acute lymphoblastic leukemia), 174.2 nM in the SJSA-1 cell line (osteosarcoma), 33.9 nM in the U87 cell line (glioblastoma), 106.3 nM in the SKUT1 cell line (uterine leiomyosarcoma), 2.4 nM in the RH5 cell line (rhabdomyosarcoma), and 6.6 nM in the REH cell line (acute lymphocytic leukemia).

I have extra information to add

SERP ratings and comments

SERP Ratings

In Cell Rating

In Model Organisms

SERP Comments:

dCDK9-202 is a potent CDK9 degrader, CRBN and proteasome dependent. In comparison with the earlier degrader THAL-SNS-032 (based on the same inhibitor), the authors report improved cellular potency and CDK9 degradation efficiency. The compound shows selectivity within a panel of CDKs, however selectivity assessment remains incomplete. In particular, the study does not examine CDK10, which is a known target of the earlier degrader THAL-SNS-032. Broad proteome-wide profiling is also missing.

(last updated: 25 Nov 2025 )

SERP Ratings

In Cell Rating

In Model Organisms

(last updated: 27 Nov 2025 )